JP2024501770A5 - - Google Patents
Info
- Publication number
- JP2024501770A5 JP2024501770A5 JP2023540926A JP2023540926A JP2024501770A5 JP 2024501770 A5 JP2024501770 A5 JP 2024501770A5 JP 2023540926 A JP2023540926 A JP 2023540926A JP 2023540926 A JP2023540926 A JP 2023540926A JP 2024501770 A5 JP2024501770 A5 JP 2024501770A5
- Authority
- JP
- Japan
- Prior art keywords
- substitution
- wild
- residue
- type human
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163134415P | 2021-01-06 | 2021-01-06 | |
| US63/134,415 | 2021-01-06 | ||
| PCT/US2022/011487 WO2022150507A1 (en) | 2021-01-06 | 2022-01-06 | Sialidase-pd-1-antibody fusion proteins and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024501770A JP2024501770A (ja) | 2024-01-15 |
| JP2024501770A5 true JP2024501770A5 (enExample) | 2025-01-09 |
Family
ID=82357533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023540926A Pending JP2024501770A (ja) | 2021-01-06 | 2022-01-06 | シアリダーゼ－ｐｄ－１－抗体融合タンパク質及びその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240059773A1 (enExample) |
| EP (1) | EP4274891A4 (enExample) |
| JP (1) | JP2024501770A (enExample) |
| KR (1) | KR20230142722A (enExample) |
| CN (1) | CN116867896A (enExample) |
| AU (1) | AU2022205638A1 (enExample) |
| CA (1) | CA3172941A1 (enExample) |
| IL (1) | IL304228A (enExample) |
| MX (1) | MX2023008029A (enExample) |
| WO (1) | WO2022150507A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7462560B2 (ja) | 2018-01-03 | 2024-04-05 | パレオン ファーマシューティカルズ インコーポレイテッド | 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびそれらの使用方法 |
| EP4744681A1 (en) | 2024-08-16 | 2026-05-20 | Shanghai Bao Pharmaceuticals Co., Ltd. | COMPLEX TARGETING TARGET CELLS AND ITS USE |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180271997A1 (en) * | 2016-05-31 | 2018-09-27 | Tianxin Wang | Methods and Reagents to Treat Tumor and Cancer |
| CN111263769B (zh) * | 2017-07-10 | 2024-01-02 | 先天制药公司 | Siglec-9中和性抗体 |
| JP7462560B2 (ja) * | 2018-01-03 | 2024-04-05 | パレオン ファーマシューティカルズ インコーポレイテッド | 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびそれらの使用方法 |
| US20250049846A1 (en) * | 2019-01-03 | 2025-02-13 | Palleon Pharmaceuticals Inc. | Methods and compositions for treating cancer with immune cells |
| CN114245807B (zh) * | 2019-06-25 | 2025-05-02 | 吉利德科学公司 | Flt3l-fc融合蛋白和使用方法 |
-
2022
- 2022-01-06 CN CN202280016348.2A patent/CN116867896A/zh active Pending
- 2022-01-06 WO PCT/US2022/011487 patent/WO2022150507A1/en not_active Ceased
- 2022-01-06 EP EP22737122.6A patent/EP4274891A4/en not_active Withdrawn
- 2022-01-06 CA CA3172941A patent/CA3172941A1/en active Pending
- 2022-01-06 US US18/260,378 patent/US20240059773A1/en active Pending
- 2022-01-06 JP JP2023540926A patent/JP2024501770A/ja active Pending
- 2022-01-06 MX MX2023008029A patent/MX2023008029A/es unknown
- 2022-01-06 AU AU2022205638A patent/AU2022205638A1/en not_active Abandoned
- 2022-01-06 KR KR1020237026708A patent/KR20230142722A/ko not_active Withdrawn
-
2023
- 2023-07-04 IL IL304228A patent/IL304228A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7291395B2 (ja) | ＩｇＧ結合ペプチド、及び該ペプチドによる抗体の特異的修飾 | |
| JP2024501771A5 (enExample) | ||
| CA2222757C (en) | Modified/chimeric superantigens and their use | |
| JP2023504914A5 (enExample) | ||
| US20210122805A1 (en) | Fc FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTS | |
| US20230218743A1 (en) | Peptide Therapeutics Against SARS-COV-2 Spike Protein | |
| JP2021508449A5 (enExample) | ||
| AU2014373593B2 (en) | Antibodies comprising C-terminal light chain polypeptide extensions and conjugates and methods of use thereof | |
| JP2022538894A5 (enExample) | ||
| JP2017527272A5 (enExample) | ||
| EP4501957A1 (en) | Anti-serum albumin nanobody and derivative thereof | |
| CN102459333A (zh) | 抗-Tau pS422抗体用于治疗脑病的应用 | |
| CA2726589A1 (en) | Fgf21 mutants and uses thereof | |
| JP2023532021A5 (enExample) | ||
| JP2019506140A5 (enExample) | ||
| JP6363623B2 (ja) | 免疫グロブリンａのレベルを増大するための方法 | |
| JP2024501767A5 (enExample) | ||
| CN104292331B (zh) | 人源抗人α干扰素抗体及其应用 | |
| CN117327174A (zh) | 抗新型冠状病毒人源化多价结合蛋白及其应用 | |
| JP2025539402A (ja) | 遺伝子操作型インターロイキン１０及びその融合タンパク質 | |
| JP2022516660A5 (enExample) | ||
| US11401309B2 (en) | Protein M fusion proteins and uses | |
| JP2024523290A5 (enExample) | ||
| JP2022532445A (ja) | 新規な中間体製造による持続型薬物結合体の製造方法 | |
| CN119798438B (zh) | 一种抗ccr8单克隆抗体及其应用 |